# To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

> **NCT02977169** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIA
- Radiotherapy

## Interventions

- **RADIATION:** PORT
- **DRUG:** Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

## Key facts

- **NCT ID:** NCT02977169
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977169, "To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02977169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*